.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

Dr Gerds on the Available JAK Inhibitors for Myelofibrosis

EP. 1: Dr Gerds on the Importance of Disease-Modifying Therapies in Myelofibrosis

October 7th 2025

Aaron T. Gerds, MD, MS, discusses the limitations of JAK inhibitors and the objectives that the development of next-generation treatments aim to achieve.

EP. 2: Dr Gerds on the Differences Between Available JAK Inhibitors for Myelofibrosis

October 8th 2025

Aaron T. Gerds, MD, MS, discusses the FDA-approved JAK inhibitors for myelofibrosis, as well as where the future of myelofibrosis management may lead.

EP. 3: Dr Gerds on the Distinct Mechanisms of Action of Approved JAK Inhibitors for Myelofibrosis

October 14th 2025

Aaron T. Gerds, MD, MS, discusses the mechanisms of action of the 4 FDA-approved JAK inhibitors available for the treatment of patients with myelofibrosis.

EP. 4: Dr Gerds on Notable Ongoing Clinical Trials in Myelofibrosis

October 21st 2025

Aaron T. Gerds, MD, MS, discusses clinical trials to watch in the evolving myelofibrosis research paradigm.